Compare Fiverr International Ltd (FVRR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Fiverr International Ltd trades at $8.63 (market cap $305.58M), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 7.6× Fiverr International Ltd's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FVRR | RXRX | |
|---|---|---|
Market Cap | $305.58M | $2.31B |
Volume | 605,109 | 40,478,768 |
Sector | Media | Health |
52-Week High | $23.60 | $6.79 |
52-Week Low | $8.47 | $2.84 |
Typical Hold Time | 62 Days | 22 Days |
Enterprise Value | $57.97M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.64, up 2.01% with bearish technical signals despite attractive valuation metrics including a P/E of 10.49 and P/S of 0.74. Recent quarterly earnings showed mixed results with Q2 2026 missing estimates, while revenue declined 10% year-over-year amid AI disruption pressures. The company maintains strong gross margins of 82% but faces challenges from AI competition compressing demand for lower-value freelance work.
The stock presents a value opportunity with discounted valuations but faces significant headwinds from AI disruption and declining revenue. Analyst consensus remains cautious with 76% hold ratings, though the $10.50 price target suggests 22% upside potential. Key risks include sustained revenue pressure from AI substitution and execution challenges in adapting the business model.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
